2021 Annual Conference | March 31 - April 2, 2021 | Online

Agenda/Recordings

Daily Agendas

click on each date to view Agenda
click on Presentation Title to view video recording

March 31, 2021 April 1, 2021 April 2, 2021

March 31, 2021

WEAR GREEN DAY - #CCFAC2021

PRESENTATION	PRESENTERS	AFFILIATION
Conference Welcome	Melinda Bachini	Cholangiocarcinoma Foundation
Cholangiocarcinoma Foundation Welcome	Stacie Lindsey	Cholangiocarcinoma Foundation
Advocacy Update	Melinda Bachini	Cholangiocarcinoma Foundation
Patient Reported Outcomes - Your Experience is a PRIORITY!	Shishir Maithel, MD and Jessica Keilson, MD	Emory University
Patient Perspective	Chaundra Bishop
Impact of the Covid-19 Pandemic on Cholangiocarcinoma	John Bridgewater, MRCP PhD FRCP	University College London, UK
Advances in Cholangiocarcinoma	Funda Meric- Bernstam, MD	MD Anderson Cancer Center
Conversation about Transplants	R. Mark Ghobrial, MD, PhD, FACS, FRCS	Houston Methodist Hospital
Map it Forward - Real World Patterns of Oncogenomic Testing in Cholangiocarcinoma	Elli Brimble, MSc, MS, CGC	Ciitizen
Caregiver Perspective - The Bright Side of "Rare"	Fred Rew
The Cholangiocarcinoma Participant Engagement and Cancer Genome Sequencing U2C Cancer Moonshot Program at Washington University in St. Louis	Ryan Fields, MD, FACS	Washington University School of Medicine
Caring for Yourself: The Mental and Emotional Impact of a Diagnosis	Julie Larson, LCSW
Nutritional and Lifestyle Research in Oncology - An Update	Robert J. Thomas, Mb ChB MRCP MD FRCR	University College London, UK
Session Wrap-up	Stacie Lindsey	Cholangiocarcinoma Foundation
15th Anniversary Pajama Party & Movie Premiere

April 1, 2021

PRESENTATION	PRESENTERS	AFFILIATION
Chair Welcome	Funda Meric-Bernstam, MD	MD Anderson Cancer Center
Cholangiocarcinoma Foundation Welcome, Mark R. Clements Awards Ceremony, Fellowship Program	Stacie Lindsey	Cholangiocarcinoma Foundation
International Cholangiocarcinoma Research Network (ICRN) Updates	Mitesh Borad, MD	Mayo Clinic
Session I: Updates on Genomically Informed Therapy in CCA Moderators: Laura Goff, MD Vanderbilt University Chiara Braconi, MD University of Glasgow, Scotland
Novel Genomic Opportunities- BAP1, CDK, ARID1A	Sarinya Kongpetch, PhD	Khon Kaen University, Thailand
Targeting HER2 in Biliary Tract Cancers	Shubham Pant, MD	MD Anderson Cancer Center
DNA Damage Repair	Timothy Yap, MBBS, PhD, FRCP	MD Anderson Cancer Center
MAPK Pathway Targeting in Cholangiocarcinoma	Ardaman Shergill, MD, MSPH	University of Chicago
Updates on Genomically Formed Therapy in CCA - IDH1/IDH2	Mitesh Borad, MD	Mayo Clinic
FGFR	Ghassan Abou-Alfa, MD, MBA	MSKCC
Panel Discussion	All
My Journey with Cholangiocarcinoma & How Raising Awareness Keeps Me Going	Jan Meyer
Session IIA: Management of Bile Duct Occlusion and Session IIB: Patient Led Data Initiatives Moderator: John Bridgewater, MRCP PhD FRCP, University College London, UK
Management of Urgent Symptoms in Cholangiocarcinoma Patients with Biliary Stents/Drains: Delphi Panel Guidelines	Juan Valle, MD	University of Manchester, UK
Biliary Emergency Care: Real World Data	Renuka Iyer, MD	Roswell Park Cancer Center
Natural Course, Management and Outcome of Patients with Cholangiocarcinoma in European Countries: An ENS-CCA Registry Study	Jesus Banales, PhD	Biodonostia Health Research Institute, Spain
Panel Discussion	All
Poster Session: Rapid Oral Abstracts & Awards
Moderators: Funda Meric-Bernstam, MD & Jesper B. Andersen, MSc, PhD
Placental growth factor promotes tumor desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma	Shuichi Aoki		Tohoku Graduate School of Medicine, Japan
Modulating cholangiocarcinoma's tumor microenvironment enhances response to immune checkpoint blockade	Laurence Diggs		National Cancer Institute
Futibatinib in patients with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2	Lipika Goyal		Harvard Medical School
Longitudinal monitoring of actionable somatic alterations in advanced cholangiocarcinoma from circulating tumor DNA profiling	Pashtoon Kasi		University of Iowa
Oncologic quality metrics for biliary tract cancer surgery – differential performance by approach	Bradford Kim		The University of Texas MD Anderson Cancer Center
Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? Implications from the neoadjuvant experience	Meredith Mason		The University of Texas MD Anderson Cancer Center
Results from the Ph 1 study of Zanidatamab in HER2-expressing biliary tract cancers & design of HERIZON-BTC-01 (Ph 2) study	Shubham Pant		The University of Texas MD Anderson Cancer Center
Potential resistance mechanisms to FGFR inhibitors (FGFRi) in FGFR2 rearranged (FGFR2 RE+) cholangiocarcinoma	Ahmed S Shalaby		The University of Texas MD Anderson Cancer Center
Caregiver Perspective from a Father	Chris Cochran
Session III: Locoregional Management of Cholangiocarcinoma Moderators: Ching-Wei Tzeng, MD, FACS - MD Anderson Cancer Center Shishir Maithel, MD - Emory University
Liver Transplantation for Intrahepatic Cholangiocarcinoma	R. Mark Ghobrial, MD	Houston Methodist Hospital
Hepatic Artery Infusion Pump for Treatment of Intrahepatic Cholangiocarcinoma	Chet Hammill, MD, MCR, FACS	Washington University in St. Louis
Surgical Management of Intrahepatic Cholangiocarcinoma	Timothy Pawlik, MD, MPH, PhD	Ohio State University Wexner Medical Center
Ablation & Chemoembolization (TACE)	Bruno Odisio, MD	MD Anderson Cancer Center
SIRT for ICC	Julien Edeline, MD	Centre Eugene Marquis, France
Radiation Therapy	Maria Hawkins, MD, MCRP, FRCR	University College London, UK
Panel Discussion	All
Closing	Stacie Lindsey	Cholangiocarcinoma Foundation

April 2, 2021

PRESENTATION	PRESENTERS	AFFILIATION
Chair Opening	John Bridgewater, MRCP PhD FRCP	University College London, UK
Cholangiocarcinoma Foundation Welcome & 15th Anniversary Celebration	Stacie Lindsey	Cholangiocarcinoma Foundation
Patient Perspective	Ellyn Goodrich
Session IV: Clinical Trials in Cholangiocarcinoma Moderators: Funda Meric-Bernstam, MD, MD Anderson Cancer Center Melinda Bachini, Cholangiocarcinoma Foundation
Clinical Trial Accrual in a Rare Cancer	Susan Pandya, MD	Agios Pharmaceuticals
Balancing Efficiency and Inclusivity to Develop Therapeutics that Work for All	Lola Fashoyin-Aje, MD, MPH	FDA
How to find a Clinical Trial for your Patients	Lipika Goyal, MD	MGH
Clinical Trial Enrollment - A Patient Perspective	Jacqui Lewis
Introduction to Cholangiocarcinoma Foundation & Ciitizen's Clinical Trial Finder	Sophia Cornew	Ciitizen
Biliary Cancers: We are Closing the GAP!	Rachna Shroff, MD	University of Arizona College of Medicine
Challenges in Clinical Trials- Interactive Discussion with Audience Q & A	All
Session V: Hilar Cholangiocarcinoma - Unravelling a Difficult Diagnosis Moderators: Milind Javle, MD, MD Anderson Cancer Center Arndt Vogel, MD, Hannover Medical School, Hannover, Germany
Case Presentations - Patient Perspective 1	Kara Thornhill
Case Presentations - Patient Perspective 2	Shlomo Yedvab
Definition of Perihilar Cholangiocarcinoma	Ryan Fields, MD, FACS	Washington University School of Medicine
Imaging of Perihilar Cholangiocarcinoma	H. Christine Kang, MD	MD Anderson Cancer Center
Perihilar Cholangiocarcinoma - pCCA: Diagnosis	Greg Gores, MD	Mayo Clinic
Management of Perihilar Cholangiocarcinoma - Surgical + Transplant	Gonzalo Sapisochin, MD	UHN University of Toronto
Management of Perihilar Cholangiocarcinoma - Medical Oncology	Arndt Vogel, MD	Hannover Medical School
Discussion Panel
Poster Session: Rapid Oral Abstracts
Moderator: John Bridgewater, MRCP, PhD, FRCP & Kabir Mody, MD
Hypercalcemia in advanced cholangiocarcinoma: prevalence, associated disease characteristics, and prognosis	Islam Baiev	Massachusetts General Hospital Cancer Center
Deconstruction of the immune microenvironment identifies tumor-immune and stroma-specific subtypes of cholangiocarcinoma	Miguel Martin	Icahn School of Medicine at Mount Sinai
A phase II study of pembrolizumab in combination with capecitabine and cxaliplatin in advanced biliary tract cancer	Cecilia Monge	National Cancer Institute
Transcriptome profiling of advanced intrahepatic CCA biopsies reveals a prognostic signature with treatment implications	Colm O'Rourke	University of Copenhagen, Denmark
Pathologic response and outcomes after neoadjuvant chemotherapy for potentially resectable intrahepatic cholangiocarcinoma	Natalia Paez Arango	The University of Texas MD Anderson Cancer Center
A phase 2 study of infigratinib in previously-treated advanced cholangiocarcinoma with FGFR2 gene fusions/rearrangements	Sameek Roychowdhury	Ohio State University
IDH1 mutation-induced metabolism potentiates the ATR-Chk1 mediated DNA damage response	LeeAnn Wang	UCSF
Retrospective analysis of biopsy outcomes for diagnosis and Next-Generation Sequencing (NGS) of cholangiocarcinoma	Karen Zhang	UCSF
Caregiver Perspective	David Craine
Session VI: Advances in Immuno-Oncology Moderators: Katie Kelley, MD - University of California, San Francisco Leonardo G. da Fonseca, MD - Cancer Institute of Sao Paulo, Brazil
Which Cholangiocarcinoma Patients Benefit from Immunotherapy?	Richard D Kim, MD	Moffitt Cancer Center
The Future of Personalized Vaccines in Cholangiocarcinoma	Nilo Azad, MD	Johns Hopkins University
HER2 Targeted Immunotherapy	Ecaterina "Cathy" Dumbrava, MD	MD Anderson Cancer Center
Immunotherapy Combinations	Oliver Klein, FRACP, MD	Austin Health, Melbourne, Australia
Discussion Panel
Conference Closing	Conference Chairs & Stacie Lindsey